Abstract
Mesial temporal lobe epilepsy (MTLE) presents with high rates of pharmacoresistance. It has been reported that even pharmacoresponsive patients may present progression of structural damage in the hippocampus. However, this association remains inconclusive. Furthermore, the progression of possible metabolic changes, such as N-acetylaspartate (NAA), a marker of neuronal damage or dysfunctio…